Canaccord analyst William Plovanic lowered the firm’s price target on AtriCure (ATRC) to $51 from $52 and keeps a Buy rating on the shares. The firm said posted a solid Q1, with revenue relatively in line with estimates and the company continuing to show better than expected adjusted EBITDA. and they continue to believe that AtriCure is a compelling name, especially given the muted tariff exposure and impacts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- Atricure’s Strong Q1 2025 Performance and Conservative Guidance Justifies Buy Rating Despite Price Target Adjustment
- AtriCure, Inc. Reports Strong Q1 2025 Growth
- AtriCure sees FY25 revenue $517M-$527M, consensus $522.85M
- AtriCure reports Q1 adjusted EPS (14c), consensus (22c)
- ATRC Upcoming Earnings Report: What to Expect?